Caring Brands (NASDAQ:CABR) Announces Earnings Results

Caring Brands (NASDAQ:CABR) released its earnings results on Tuesday. The company reported ($0.27) earnings per share for the quarter, Zacks reports.

Caring Brands Stock Performance

NASDAQ:CABR traded up $0.16 during trading hours on Tuesday, hitting $1.07. 173,039 shares of the company’s stock traded hands, compared to its average volume of 123,815. The stock has a market cap of $9.57 million and a price-to-earnings ratio of -2.89. Caring Brands has a twelve month low of $0.71 and a twelve month high of $5.35. The company has a debt-to-equity ratio of 0.03, a quick ratio of 13.09 and a current ratio of 13.16. The stock has a fifty day moving average price of $1.03.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Caring Brands stock. Jane Street Group LLC purchased a new stake in shares of Caring Brands, Inc. (NASDAQ:CABR) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned 0.25% of Caring Brands at the end of the most recent quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings began coverage on shares of Caring Brands in a research report on Monday, January 26th. They set a “sell (e)” rating on the stock. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.